Pyrimidinylpyrroloquinolones as Highly Potent and Selective PDE5 Inhibitors for Treatment of Erectile Dysfunction
Authors:
- 9 August 2002
- journal article
- letter
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (19) , 4094-4096
Abstract
A series of N-pyrimidinylpyrroloquinolones were discovered as extremely potent and selective PDE5 inhibitors. Representative compounds demonstrated in vivo efficacy in dog erectile dysfunction models and are orally bioavailable.Keywords
This publication has 7 references indexed in Scilit:
- Novel, Potent, and Selective Phosphodiesterase 5 Inhibitors: Synthesis and Biological Activities of a Series of 4-Aryl-1-isoquinolinone DerivativesJournal of Medicinal Chemistry, 2001
- Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functionsCurrent Opinion in Cell Biology, 2000
- Cyclic GMP Phosphodiesterase-5: Target of SildenafilJournal of Biological Chemistry, 1999
- Section Review Cardiovascular & Renal: Phosphodiesterase 5 inhibitors in development for cardiovascular therapyExpert Opinion on Investigational Drugs, 1996
- Cyclic nucleotide phosphodiesterases: functional implications of multiple isoformsPhysiological Reviews, 1995
- Reaktionen an Indolderivaten, XVII. Die biogenetisch orientierte Totalsynthese von DL‐Camptothecin und 7‐Chlor‐camptothecinEuropean Journal of Inorganic Chemistry, 1972
- Reaktionen an Indolderivaten, XVI. Die autoxydative Indol‐Chinolon‐Umwandlung eines Camptothecin‐ModellsEuropean Journal of Inorganic Chemistry, 1972